Summary
Nosocomial pneumonia is among the most frequent infections in the intensive care unit with high morbidity and mortality. The decisive factor for treatment failure is inadequate previous antibiotic treatment. Broad spectrum and sufficiently high dosed initial treatment is crucial.
To prevent further resistances, the antibiotic treatment must be evaluated early. Depending on the treatment success, treatment has to be changed or terminated. Deescalation is possible and sensible after three days. A treatment period of seven days should not routinely be exceeded. The treatment recommendations should be adapted to local resistances and the local statistics of frequent pathogens. A further factor for treatment decision-making is the risk analysis of the patient (previous treatment, stays in hospitals or nursing homes, concomitant diseases).
Zusammenfassung
Nosokomiale Pneumonie sind die häufigsten Intensivinfektionen mit hoher Morbidität und Letalität. Die primär inadäquate Antibiotikatherapie ist der entscheidende Faktor für Therapieversagen. Eine möglichst breite hochdosierte Initialtherapie ist daher zwingend erforderlich. Um die weitere Resistenzentwicklung zu vermeiden muss die Antibiotikatherapie frühzeitig evaluiert werden und in Abhängigkeit vom Therapieerfolg beendet oder gewechselt werden.
Deeskalationstherapie ab Tag 3 ist möglich und sinnvoll. Eine Therapiedauer von 7 Tagen sollte nur in Einzelfällen überschritten werden. Therapieempfehlungen müssen entsprechend der lokalen Resistenz- und Erregerstatistiken angepasst werden. Die Risikofaktorenanalyse des Patienten (Vortherapie, Lebensraum, Begleiterkrankungen) fließt in die Therapieüberlegungen ein.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Literatur
Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, Wolff M, Spencer RC, Hemmer M (1995) The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 274(8):639-644
Alberti C, Brun-Buisson C, Chevret S, Antonelli M, Goodman SV, Martin C, Moreno R, Ochagavia AR, Palazzo M, Werdan K, Le Gall JR (2005) European Sepsis Study Group.Systemic inflammatory response and progression to severe sepsis in critically ill infected patients. Am J Respir Crit Care Med 171(5):461–468
Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C (2003) Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med (12):2742–2751
Dietrich ES, Demmler M, Schulgen G, Fekec K, Mast O, Pelz K, Daschner FD (2002) Nosocomial pneumonia: a cost-of-illness analysis. Infection 30 (2):61–67
Cosgrove SE (2006) The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis 42(Suppl 2:S82–89
Pletz MW, Welte T (2005) Pneumonie. In: Dietel M, Suttorp N, Zeitz M (Hrsg) Harrison’s Innere Medizin (dt. Ausgabe), ABW Wissenschaftsverlag GmbH, Berlin, S 1638–1650
Gastmeier P, Sohr D, Geffers C, Behnke M, Daschner F, Ruden H (2005) Mortality risk factors with nosocomial Staphylococcus aureus infections in intensive care units: results from the German Nosocomial Infection Surveillance System (KISS). Infection 33(2):50–55
Martin GS, Mannino DM, Eaton S, Moss M (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348(16):1546–1554
el-Ebiary M, Torres A, Fabregas N, de la Bellacasa JP, Gonzalez J, Ramirez J, del Bano D, Hernandez C, Jimenez de Anta MT (1997) Significance of the isolation of Candida species from respiratory samples in critically ill, non-neutropenic patients. An immediate postmortem histologic study. Am J Respir Crit Care Med 156(2 Pt 1):583–590
Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans WE, Van Wijngaerden E (2004) Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med 170(6):621–625
National Nosocomial Infections Surveillance System (2004) National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 32(8):470–485
Huotari K, Tarkka E, Valtonen V, Kolho E (2003) Incidence and risk factors for nosocomial infections caused by fluoroquinolone-resistant Escherichia coli. Eur J Clin Microbiol Infect Dis 22(8):492–495
Hong T, Moland ES, Abdalhamid B, Hanson ND, Wang J, Sloan C, Fabian D, Farajallah A, Levine J, Thomson KS (2005) Escherichia coli: development of carbapenem resistance during therapy. Clin Infect Dis 40(10):e84–86
Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP (2003) Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 289(7):885–888
Grundmann H, Barwolff S, Tami A, Behnke M, Schwab F, Geffers C, Halle E, Gobel UB, Schiller R, Jonas D, Klare I, Weist K, Witte W, Beck-Beilecke K, Schumacher M, Ruden H, Gastmeier P (2005) How many infections are caused by patient-to-patient transmission in intensive care units? Crit Care Med 33(5):946–951
Goossens H, Ferech M, Vander Stichele R, Elseviers M (2005) Out-patient antibiotic use in Europe and association with resistance: a cross national database study. Lancet 365:579–587
Welte T (2004) Epidemiological impact of antibiotic use/misuse in the community. Eur Respir Mon 28:165–174
Pletz MW, McGee L, Van Beneden CA, Petit S, Bardsley M, Barlow M, Klugman KP (2006) Fluoroquinolone resistance in invasive Streptococcus pyogenes isolates due to spontaneous mutation and horizontal gene transfer. Antimicrob Agents Chemother 50(3):943–948
Namias N, Samiian L, Nino D, Shirazi E, O’Neill K, Kett DH, Ginzburg E, McKenney MG, Sleeman D, Cohn SM (2000) Incidence and susceptibility of pathogenic bacteria vary between intensive care units within a single hospital: implications for empiric antibiotic strategies. J Trauma 49(4):638–645
Metlay JP, Schulz R, Li YH, Singer DE, Marrie TJ, Coley CM, Hough LJ, Obrosky DS, Kapoor WN, Fine MJ (1997) Influence of age on symptoms at presentation in patients with community-acquired pneumonia. Arch Intern Med 157(13):1453–1459
Hopstaken RM, Butler CC, Muris JW, Knottnerus JA, Kester AD, Rinkens PE, Dinant GJ (2006) Do clinical findings in lower respiratory tract infection help general practitioners prescribe antibiotics appropriately? An observational cohort study in general practice. Fam Pract 23(2):180–187
Pugin J, Auckenthaler R, Mili N, Janssens JP, Lew PD, Suter PM (1991) Diagnosis of ventilator-associated pneumonia by bacterologic analysis of bronchoscopic and nonbronchoscopic “blind” bronchoalveolar fluid. Am Rev Respir Dis 143:1121–1129
Kollef MH, Von Harz B, Prentice D, Shapiro SD, Silver P, St John R, Trovillion E (1997) Patient transport from intensive care increases the risk of developing ventilator-associated pneumonia. Chest 112(3):765–773
Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, Müller B (2004) Effect of procalcitonin guided treatment on antibiotic use andoutcome inlower respiratory tract infections. Lancet 363:600–607
Ewig S, de Roux A, Bauer T, Garcia E, Mensa J, Niederman M, Torres A (2004) Validation of predictive rules and indices of severity for community acquired pneumonia. Thorax 59(5):421–427
Fagon JY, Chastre J, Wolff M, Gervais C, Parer-Aubas S, Stephan F, Similowski T, Mercat A, Diehl JL, Sollet JP, Tenaillon A (2000) Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. Ann Intern Med 132(8):621–630
Ruiz M, Torres A, Ewig S, Marcos MA, Alcon A, Lledo R, Asenjo MA, Maldonaldo A (2000) Noninvasive versus invasive microbial investigation in ventilator-associated pneumonia: evaluation of outcome. Am J Respir Crit Care Med 162(1):119–125
Maskell NA, Gleeson FV, Darby M et al (2004) Diagnostically significant variations in pleural fluid pH in loculated parapneumonic effusions Chest 126:2022–2024
Hoffken G, Lorenz J, Kern W, Welte T, Bauer T, Dalhoff K, Dietrich E, Ewig S, Gastmeier P, Grabein B, Halle E, Kolditz M, Marre R, Sitter H (2005) S3-Leitlinie zu ambulant erworbener Pneumonie und tiefen Atemwegsinfektionen. Pneumologie 59(9):612–664
Tablan OC, Anderson LJ, Besser R, Bridges C, Hajjeh R (2004) CDC; Healthcare Infection Control Practices Advisory Committee. Guidelines for preventing health-care–associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep 53(RR-3):1–36
Valles J, Rello J, Ochagavia A, Garnacho J, Alcala MA (2003) Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival. Chest 123(5):1615–1624
Luna CM, Vujacich P, Niederman MS, Vay C, Gherardi C, Matera J, Jolly EC (1997) Impact of BAL data on the therapy and outcome of ventilatorassociated pneumonia. Chest 111(3):676–685
Trouillet JL, Chastre J, Vuagnat A, Joly-Guillou ML, Combaux D, Dombret MC, Gibert C (1998) Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 157(2):531–539
American Thoracic Society; Infectious Diseases Society of America (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171(4):388–416
Sandiumenge A, Diaz E, Bodi M, Rello J (2003) Therapy of ventilator-associated pneumonia. A patient-based approach based on the ten rules of “The Tarragona Strategy”. Intensive Care Med 29(6):876–883
Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL (2000) Shortcourse empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 162(2 Pt 1):505–511
Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, Perrin D, Fieux F, Aubas S (2003) PneumA Trial Group. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 290(19):2588–2598
Dunbar LM, Khashab MM, Kahn JB, Zadeikis N, Xiang JX, Tannenberg AM (2004) Efficacy of 750-mg, 5-day levofloxacin in the treatment of community acquired pneumonia caused by atypical pathogens. Curr Med Res Opin 20(4):555–563
Halm EA, Teirstein AS (2002) Clinical practice. Managment of community–acquired pneumonia. N Engl J Med 347(25):2039-2045
Arancibia F, Bauer TT, Ewig S, Mensa J, Gonzalez J, Niederman MS, Torres A (2002) Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 162:1849–1858
Giantsou E, Liratzopoulos N, Efraimidou E, Panopoulou M, Alepopoulou E, Kartali-Ktenidou S, Minopoulos GI, Zakynthinos S, Manolas KI (2005) Both early-onset and late-onset ventilator associated-pneumonia are caused mainly by potentially multiresistant bacteria. Intensive Care Med 31(11):1488–1494
Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L (2004) Beta lactam monotherapy versus beta lactamaminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and metaanalysis of randomised trials. BMJ 328(7441):668
Safdar N, Handelsman J, Maki DG (2004) Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A metaanalysis. Lancet Infect Dis 4(8):519–527
Hoffman LR, D’Argenio DA, MacCoss MJ, Zhang Z, Jones RA, Miller SI (2005) Aminoglycoside antibiotics induce bacterial biofilm formation. Nature 436(7054):1171–1175
Chamot E, Boffi El Amari E, Rohner P, Van Delden C (2003) Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 47(9):2756–2764
Mayer I, Nagy E (1999) Investigation of the synergic effects of aminoglycoside-fluoroquinolone and third-generation cephalosporin combinations against clinical isolates of Pseudomonas spp. J Antimicrob Chemother 43(5):651–657
Burkhardt O, Derendorf H, Welte T (2006) Neue Antibiotika für die Behandlung von MRSA-Infektionen. Med Monatsschr Pharm 29(2):56–62
Rello J, Sole-Violan J, Sa-Borges M, Garnacho-Montero J, Munoz E, Sirgo G, Olona M, Diaz E (2005) Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. Crit Care Med 33(9):1983–1987
Welte T (2006) Arzneimittelkommission der deutschen Ärzteschaft (Hrsg) Arzneiverordnungen. Deutscher Ärzte-Verlag, Köln, S 879–891
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Welte, T. Die nosokomiale Pneumonie. Intensivmed 43, 301–309 (2006). https://doi.org/10.1007/s00390-006-0721-2
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s00390-006-0721-2